22 Jan 2019

The J.P. Morgan Healthcare Conference is a time for industry to reflect, assess, and forecast, and this year’s 37th annual conference was no exception.

Below is a summary of the most important news from JPM 2019, as selected by BulletinHealthcare’s expert analysts.

M&A Activity 

Eli Lilly Rushed Loxo Acquisition Through To Make Big Splash At JPM19: BioPharma Dive, Axios, Endpoints News, STAT, Business Insider

Analysts: Mega-Deals At Bristol-Myers, Lilly Could Bode For Big Year In Pharma M&A: Business Insider, FirstWordPharma, Fierce Biotech

Analysts Offer Thoughts On BMS-Celgene Merger: MedCity News 


Pfizer Staying In Neuroscience By Funding Startups: Business Insider 

GlaxoSmithKline Looking For Early-Development Treatments And New Partnerships: Reuters, FirstWordPharma

Drug Developments

Sandoz, Pear Therapeutics Unveil Commercial Launch Of Digital Therapy For Opioid Use Disorder: Drug Delivery Business News,  Monthly Prescribing Reference,  BioSpectrum

J&J Expecting Big Things In Immunology From Tremfya: Fierce Pharma Marketing

Sage Preparing To Launch Two Postpartum Depression Drugs: Boston Business Journal

Other News of Note

Novartis CEO Vas Narasimhan’s Presentation At JPM19, CNBC Interview: BioSpaceFirstWordPharma, The Street

CVS Commits $100M For Community Health Programs: U.S. News & World Report, CNBC


Analysis: Executives Come Away From JPM19 With “Cautious Optimism:” Fierce Pharma 

Biotech A Safe Bet, More Deals On the Horizon: Financial Times

Analysis Examines NASH Insights From JPM19: BioPharma Dive

For more insights like these, follow us on LinkedIn and watch this space!